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The complete amino acid sequence of porcine muscarinic acetylcholine receptor Ill has been deduced by cloning and 
sequencing the genomic DNA. The antagonist binding properties of muscarinic acetylcholine receptor Ill expressed from 
the cloned DNA in Xenopus oocytes correspond most closely to those of the pharmacologically defined MZ glandular 
(Ill) subtype. 
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1. INTRODUCTION 
Pharmacologically distinguishable forms of the 
muscarinic acetylcholine receptor (mAChR) occur 
in different tissues and have been classified into M1 
(I), MZ cardiac (II) and Mz glandular (Ill) subtypes 
on the basis of their difference in apparent affinity 
for antagonists [l-3]. The primary structures of 
two mAChR species, designated as mAChR 1 and 
mAChR 11, have been elucidated by cloning and 
sequence analysis of DNAs complementary to the 
porcine cerebral and cardiac mRNAs, respectively 
[4-61. Microinjection of Xenopus oocytes with 
mRNAs synthesized by transcription in vitro of the 
cloned cDNAs has generated functional mAChR 1 
and mAChR 11, which differ from each other both 
in acetylcholine-induced response and in 
antagonist-binding properties [4,7]. These results, 
together with the differential tissue location of the 
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two mAChR mRNAs [4,5], have indicated that 
distinct gene products underlie pharmacologically 
different mAChR subtypes. The primary struc- 
tures of two additional mAChR species, mAChR 
III and mAChR IV (defined as in [SJ), have subse- 
quently been predicted from the nucleotide se- 
quences of the cloned cerebral cDNAs or genomic 
DNAs from rat and man [8,9]. The present paper 
describes the complete amino acid sequence of por- 
cine mAChR Ill deduced from the cloned genomic 
DNA. mAChR Ill which has been produced in 
Xenopus oocytes by microinjection of mRNA syn- 
thesized by transcription in vitro of the cloned 
DNA is compared with the three other mAChR 
species produced similarly with respect to binding 
affinities for selective antagonists. 
2. MATERIALS AND METHODS 
Rat genomic DNAs encoding mAChR Ill and mAChR IV 
(clones ArmACR14 and hrmACR38) were obtained by screening 
libraries constructed in ACharon 4A (Clontech) [IO] and 
AEMBLJ [ll], respectively, using oligodeoxyribonucleotide 
probes prepared with an automatic DNA synthesizer (Applied 
Biosystems) on the basis of rat cDNA sequences (nucleotides 
931-989 and 1197-1226 for mAChR 111; nucleotides 700-752 
and 1053-1080 for mAChR IV) [8]. Porcine genomic DNA en- 
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coding mAChR III was isolated by screening a library con- 
structed in XEMBL3 using the nick-translated 1.3-kilobasepair 
(kb) PvuII fragment from hrmACR14 as a probe. From -7 x 
lo5 plaques, two positive clones were obtained. The -2.9-kb 
BumHI fragment hybridizable with the probe, derived from one 
of these clones (XpmACR2), was subcloned in plasmid pUC18 
[12] to yield plasmid pSpmACR7, which was subjected to 
nucleotide sequence analysis [ 13,141. 
pSpmACR7 was cleaved by TthlllI, treated with Tb DNA 
polymerase in the presence of the four deoxyribonucleoside 
triphosphates (blunt-ended), ligated with the synthetic XbaI 
linker 5’-CTCTAGAG-3’ and cleaved by XbaI and SmaI. The 
resulting -2.1-kb fragment, the -320-basepair (bp) 
NueI(2255)/EcoRI(on vector) fragment from plasmid pSPBM1 
[7] and the 3.0-kb EcoRI/XbuI fragment from plasmid pSP64 
[15] were ligated to yield plasmid pSPPM3; the NueI site is 
specified by the number indicating the 5’-terminal nucleotide 
generated by cleavage [4]. The 2.5-kb TthlllI/BumHI frag- 
ment from hrmACR14 was blunt-ended, ligated with the XbuI 
linker and cleaved by Xbul and FnuDII. The resulting -1.8-kb 
fragment, the -320-bp NueI(2255)/EcoRI(on vector) fragment 
from pSPBM1 and the 3.0-kb EcoRI/Xbul fragment from 
pSP64 were ligated to yield plasmid pSPRM3. The -3.&J-kb 
BumHI/Su/I fragment from hrmACR38 was blunt-ended, 
ligated with the synthetic Hind111 linker 5 ‘-ACAAGCTTGT-3’ 
and cleaved by PvuI and HindHI. The resulting -1.2-kb 
PvuI/HindIII fragment was isolated. The -0.8-kb HinfI frag- 
ment excised from the -3.8-kb BumHI/Su!I fragment from 
hrmACR38 was blunt-ended, ligated with the Hind111 linker 
and cleaved by Hind111 and PvuI. The resulting -0.5-kb Hin- 
dIII/PvuI fragment, the above-mentioned -1.2-kb PvuI/Hin- 
dII1 fragment and the -3.7-kb Hind111 fragment from 
pSPBM1 were ligated to yield plasmid pSPRM4 carrying the 
protein-coding sequence in the same orientation as the SP6 pro- 
moter. mRNAs specific for porcine mAChR III, rat mAChR III 
and rat mAChR IV were synthesized by transcription in vitro 
[ 15,161 using EcoRI-cleaved pSPPM3, EcoRI-cleaved pSPRM3 
and XbuI-cleaved pSPRM4 as templates, respectively. The 
resulting mRNAs were shown by electrophoresis on 1.5% 
agarose gel to be homogeneous and to have expected sizes of 
-2.4, -2.1 and -2.4 kilobases, respectively. mRNAs specific 
for porcine mAChR I and mAChR II were synthesized as in [7]. 
Each mRNA was injected into Xenopus luevis oocytes (mRNA 
concentration, 1 pg/J; average volume injected per oocyte, 
-40 nl). The injected oocytes were incubated at 19°C for 3 days 
as in [4] before cell extracts from them were prepared for ligand 
binding assays. (-)-[‘H]Quinuclidinyl benzilate-binding activi- 
ty was assayed as in [4], except that 0.42 nM ( -)-[3H]QNB 
(spec. act. of 30 Ci/mmol) was used. 
3. RESULTS AND DISCUSSION 
Nucleotide sequence analysis of the -2.9-kb 
BumHI fragment derived from the porcine 
genomic DNA clone hpmACR2 (see section 2) 
reveals an open reading frame of 1770 nucleotides 
(fig.1). It is concluded that this reading frame en- 
codes porcine mAChR III because the predicted se- 
quence of 590 amino acid residues (calculated M, 
258 
66074) shows 94% and 96% identity with the rat 
[8] and human mAChR III sequences [9], respec- 
tively. The protein-coding region of the porcine 
mAChR III gene contains no introns as is the case 
for the other mAChR genes hitherto reported 
hW. 
Porcine mAChR III shares characteristic struc- 
tural features with the other mAChR species 
documented [4-6,8,9,17]. Its hydropathy profile 
[18] suggests the presence of seven putative 
transmembrane cY-helices (segment I, amino acid 
residues 68-91; II, 105-125; III, 143-164; IV, 
185-207; V, 230-252; VI, 493-513; VII, 
528-547); segment VII is less hydrophobic than 
the other segments. Porcine mAChR III also has 
the two conserved aspartic acid residues (residue 
114 in segment II and residue 148 in segment III), 
and its amino-terminal region preceding segment I
contains several potential sites of N-glycosylation 
[19] (asparagine residues 6, 7, 15, 41, 48 and 53); 
N-glycosylation of residues 6 and 7 may be mutual- 
ly exclusive. Its carboxy-terminal region contains 
several potential sites of phosphorylation 
(threonine residues 550, 553 and 554 and serine 
residue 578). 
mRNAs specific for porcine and rat mAChR III 
were synthesized by transcription in vitro of the 
respective cloned DNAs and were injected into 
Xenopus oocytes. The resulting mAChR III 
species were examined for antagonist-binding pro- 
perties, using oocyte extracts, in comparison with 
mAChR I, mAChR II and mAChR IV produced 
similarly. The apparent dissociation constant (&) 
for ( -)-[3H]QNB was similar for all the mAChR 
species (84-130 pM) (table 1). The apparent Kd 
values for selective antagonists were obtained by 
measuring displacement of (- )-[3H]QNB binding 
by increasing concentrations of the antagonists 
(fig.2 and table 1). Hexahydrosiladifenidol, selec- 
tive for the M2 glandular (III) subtype relative to 
the MZ cardiac (II) subtype [3,21,22], showed the 
highest binding affinity for mAChR III (Kd = 
4.0-4.4 nM). The affinity for this antagonist 
decreased in the order of mAChR IV (Kd = 
20 nM), mAChR I (Kd = 5 1 nM) and mAChR II 
(Kd = 280 nM). Pirenzepine, selective for the Mi 
(I) subtype [l], exhibited the highest affinity for 
mAChR I (Kd = 18 nM). mAChR III and mAChR 
IV showed intermediate affinities for pirenzepine 
(Kd = 120-180 nM), and mAChR II the lowest af- 
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1 10 20 30 
Met Thr Leu His Asn Asn Asn Thr Thr Ser Pro Leu Phe Pro Asn Ile Ser Ser Ser Trp Ile His Gly Pro Ser AsP Ala GlY Leu Pro 
ATG ACC TTG CAC AAT AAC AAT ACA ACC TCA CCT TTG TTT CCA AAC ATC AGC TCT TCC TGG ATT CAC GGC CCT TCC GA1 GCA GGG CTG ccc 
40 50 60 
Pro Gly Thr Val Thr His Phe Gly Ser Tyr Asn Ile Ser Gln Ala Ala Gly Asn Phe Ser Ser Pro Asn Gly Thr Thr .br ASP Pro Leu 
CCA GGA ACG GTT ACT CAT TTT GGC AGC TAC AAC ATT TCT CAG GCA GCT GGG AAT TTC TCC TCT CCA AAT GGC ACC ACC AGT fiAC CCT CTG 
70 80 90 
Gly Gly His Thr Ile Trp Gln Val Val Phe Ile Ala Phe Leu Thr Gly Ile Leu Ala Leu Val Thr Ile Ile Gly Asn Ile Leu Val Ile 
GGA GGT CAC ACC ATC TGG CAA GTG GTG TTC ATT GCA TTC TTA ACA GGC ATC CTG GCC TTG GTG ACT ATC ATC GGC AAT ATC CTG GTG ATC 
100 110 120 
Val Ala Phe Lys Val Asn Lys Gln Leu Lys Thr Val Asn Asn Tyr Phe Leu Leu Ser Leu Ala Cys Ala Asp Leu Ile Ile Gly Val Ile 
GTG GCA TTC PAG GTC AAC AAG CAA CTG AAG ACA GTC AAC AAC TAC TTC CTC TTA AGT CTG GCC TGT GCT GAC CTG ATT ATC GGG GTC ATT 
130 140 150 
Ser Met Asn Leu Phe Thr Thr Tyr Ile Ile Met Asn Arg Trp Ala Leu Gly Asn Leu Ala Cys Asp Leu Trp Leu Ser Ile Asp Tyr VaI 
TCA ATG AAT CTG TTT ACT ACC TAC ATC ATC ATG AAT CGA TGG GCT TTA GGG AAC TTG GCC TGT GAC CTC TGG CTT TCC ATT GAC TAT GTG 
160 170 180 
Ala Ser Asn Ala Ser Val Met Asn Leu Leu Val Ile Ser Phe Asp Arg Tyr Phe Ser Ile Thr Arg Pro Leu Thr Tyr Arg Ala Lys Arg 
GCT AGC AAT GCC TCG GTC ATG AAT CTT CTG GTC ATT AGC TTT GAC AGG TAC TTT TCC ATC ACG AGG CCG CTC ACA TAC CGA GCC AAA AGA 
190 200 210 
Thr Thr Lys Arg Ala Gly Val Met Ile Gly Leu Ala Trp Val Ile Ser Phe Ile Leu Trp Ala Pro Ala Ile Leu Phe Trp Gln Tyr Phe 
ACA ACA AAG CGA GCT GGT GTG ATG ATA GGT CTG GCT TGG GTC ATC TCC TTC ATC CTT TGG GCT CCT GCC ATC TTG TTC TGG CAA TAC TTT 
220 230 240 
Val Gly Lys Arg Thr Val Pro Pro Gly Glu Cys Phe Ile Gln Phe Leu Ser Glu Pro Thr Ile Thr Phe Gly Thr Ala Ile Ala Ala Phe 
GTT GGG MG AGA ACT GTC CCT CCA GGA GAG TGT TTC ATC CAG TTC CTC AGT GAG CCC ACC ATC ACC TTC GGC ACG GCC ATC GCT GCC TTT 
250 260 270 
Tyr Met Pro Val Thr Ile Met Thr Ile Leu Tyr Trp Arg Ile Tyr Lys Glu Thr Glu Lys Arg Thr Lys Glu Leu Ala Gly Leu Gln Ala 
TAT ATG CCT GTC ACC ATT ATG ACT ATT TTA TAC TGG AGG ATC TAT AAG GAA ACT GAd APA CGT ACC AAA GAG CTT GCC GGG CTG CAA GCC 
280 290 300 
Ser Gly Thr Glu Ala Glu Ala Glu Asn Phe Val His Pro Thr Gly Ser Ser Arg Ser Cys Ser Ser Tyr Glu Leu Gln Gln Gln Ser Leu 
TCT GGG ACA GAG GCA GAG GCA GAA AAC TTT GTT CAC CCC ACA GGT AGT TCT CGG AGC TGC AGC AGC TAT GAG CTT CAG CAG CAA AGC CTG 
310 320 330 
Lys Arg Ser Ala Arg Arg Lys Tyr Gly Arg Cys His Phe Trp Phe Thr Thr Lys Ser Trp Lys Pro Ser Ala Glu Gln Met Asp Gln Asp 
AAA CGC TCA GCC AGG AGG AAG TAT GGA CGC TGC CAC TTC TGG TTC ACA ACC AAG AGC TGG AAG CCC AGT GCT GAG CAG ATG GAC CAA GAC 
340 350 360 
His Ser Ser Ser Asp Ser Trp Asn Asn Asn Asp Ala Ala Ala Ser Leu Glu Asn Ser Ala Ser Ser Asp Glu Glu Asp ile Gly Ser Glu 
CAC AGC AGC AGT GAC AGC TGG AAT AAC AAT GAT GCT GCT GCC TCC CTG GAd AAC TCC GCC TCC TCC GAT GAG GAG GAC ATT GGC TCA GAA 
370 380 390 
Thr Arg Ala Ile Tyr Ser Ile Val Leu Lys Leu Pro Gly His Ser Thr Ile Leu Asn Ser Thr Lys Leu Pro Ser Ser Asp Asn Leu Gln 
ACA AGA GCC ATC TAC TCC ATC GTG CTC AAG CTT CCA GGT CAC AGC ACC ATC CTC AAC TCC ACC AAG TTA CCG TCT TCA GAC AAC CTG CAG 
400 410 420 
Val Pro Glu Glu Glu Leu Gly Thr Val Asp Leu Glu Arg Lys Ala Ser Lys Leu Gln Ala Gln Lys Ser Met Asp Asp Gly Gly Ser Phe 
GTG CCC GAG GAG GAG CTG GGG ACA GTG GAC TTG GAG AGA AAA GCC AGC AAA CTG CAA GCC CAG AAG AGC ATG GAC GAT GGA GGC AGT TTT 
430 440 450 
Gln Lys Ser Phe Ser Lys Leu Pro Ile Gln Leu Glu Ser Ala Val Asp Thr Ala Lys Ala Ser Asp Val Asn Ser Ser Val Gly Lys Thr 
CAA AAA AGC TTC TCC AAG CTT CCC ATC CAG TTA GAG TCA GCC GTG GAC ACA GCC AAG GCC TCT GAT GTC AAC TCC TCA GTG GGT AAG ACC 
460 470 480 
Thr Ala Thr Leu Pro Leu Ser Phe Lys Glu Ala Thr Leu Ala Lys Arg Phe Ala Leu Lys Thr Arg Ser Gln Ile Thr Lys Arg Lys Arg 
ACG GCC ACT CTA CCT CTG TCC TTT AAG GAA GCT ACT CTG GCC AAG AGG TTT GCT CTG AAG AX AGA AGT CAG ATC ACC AAG CGG AAA CGG 
490 500 510 
Met Ser Leu Ile Lys Glu Lys Lys Ala Ala Gln Thr Leu Ser Ala Ile Leu Leu Ala Phe Ile Ile Thr Trp Thr Pro Tyr Asn Ile Met 
ATG TCG CTC ATC AAG GAG AAG AAA GCG GCC CAG ACC CTC AGC GCC ATC TTG CTT GCC TTC ATC ATC ACC TGG ACC CCC TAC AAT ATC ATG 
520 530 540 
Val Leu Val Asn Thr Phe Cys Asp Ser Cys Ile Pro Lys Thr Tyr Trp Asn Leu Gly Tyr Trp Leu Cys Tyr Ile Asn Ser Thr Val Asn 
GTT CTG GTG AAC ACC TTT TGT GAC AGC TGC ATA CCC AAA ACC TAT TGG AAT CTG GGC TAC TGG CTG TGC TAC ATC AAC AGC ACC GTG AAC 
550 560 570 
Pro Val Cys Tyr Ala Leu Cys Asn Lys Thr Phe Arg Thr Thr Phe Lys Met Leu Leu Leu Cys Gln Cys Asp Lys Arg Lys Arg Arg Lys 
CCC GTG TGC TAT GCC CTG TGC AAC AAA ACA TTC AGA ACC ACT TTC AAG ATG CTG CTG CTG TGC CAG TGT GAC AAA AGG AAG AGG CGC AAG 
-1 
90 
180 
270 
360 
450 
540 
630 
720 
810 
900 
990 
1080 
1170 
1260 
1350 
1440 
1530 
1620 
1710 
580 590 
Gln Gln Tyr Gln Gln Arg Gln Ser Val Ile Phe His Lys Arg Val Pro Glu Gln Ala Leu 
CAG CAG TAT CAG CAA AGA CAG TCA GTC ATT TTC CAC AAG CGG GTG CCC GAG CAG GCC TTG TAG AAGGAGGCGTTGTCCATAGCAGTCACCAAACGCACA 1809 
CATCAGCCCACA-----3' 1821 
Fig.1. Nucleotide sequence of the porcine genomic DNA encoding mAChR III. The nucleotide sequence of the message strand, 
together with the deduced amino acid sequence, is shown. Nucleotide residues are numbered in the 5 ’ to 3 ’ direction, beginning with 
the first residue of the ATG triplet encoding the initiating methionine, and the nucleotides on the 5’-side of residue 1 are indicated 
by negative numbers; the number of the nucleotide residue at the right end of each line is given. Amino acid residues are numbered 
beginning with the initiating methionine. 
259 
Volume 235, number 1,2 FEBS LETTERS 
Table I 
Apparent dissociation constants (Kd) of molecularly defined mAChR species for antagonists 
Antagonist Kd (M) 
mAChR I mAChR II mAChR III mAChR III mAChR IV 
(porcine) (porcine) (porcine) (rat) (rat) 
(- )-13WQNB 8.4 x lo-” 1.3 x lo-‘0 1.2 x 10-10 1.0 x 10-10 9.5 x lo-” 
Hexahydrosiladifenidol 5.1 x 10-S 2.8 x lo-’ 4.4 x 10-9 4.0 x 1om9 2.0 x 10-s 
Pirenzepine 1.8 x lo-* 6.6 x 10-7 1.8 x lo-’ 1.3 x lo-’ 1.2 x 10-7 
AF-DX 116 2.5 x lO-6 7.3 x 10-7 2.3 x 1O-6 3.1 x 10-s 2.3 x 1O-6 
The apparent Kd values for (-)-[‘H]QNB (means of 3 experiments) were obtained by Scatchard 
analysis, and those for hexahydrosiladifenidol, pirenzepine and AF-DX 116 were calculated from the 
I& values derived from fig.2 [20] 
August 1988 
finity (& = 660 nM). These three classes of 
binding affinity for pirenzepine are similar to those 
reported originally for mAChRs in brain (cerebral 
cortex and hippocampus), glands and heart [l]. 
AF-DX 116, selective for the MZ cardiac (II) sub- 
type [2], exhibited a higher affinity for mAChR II 
(& = 0.73 PM) than for the other mAChR species 
(& = 2.3-3.1 PM). The apparent & values of 
mAChR I and mAChR II for (-)-[3H]QNB, 
pirenzepine and AF-DX 116 are in agreement with 
those obtained in our previous studies [4,7]. Dif- 
ferential binding affinities for pirenzepine and AF- 
DX 116 have also been reported for different rat 
and human mAChR species expressed from the 
cloned DNAs in mammalian cells [8,9]. 
The results described above indicate that 
mAChR I, mAChR II and mAChR III correspond 
Fig.2. Effects of hexahydrosiladifenidol (A), pirenzepine (B) 
and AF-DX 116 (C) on (-)-[‘H]QNB binding in extracts from 
Xenopus oocytes injected with the mRNA specific for porcine 
mAChR I (0), porcine mAChR II (0). porcine mAChR III 
(A), rat mAChR III (A) or rat mAChR IV (0). Data are from 
2-4 experiments. Values for 100% and 0% binding were 
determined by measurements in the absence of antagonists and 
in the presence of 10 ,uM atropine, respectively. The 0% values 
[59-153 dpm (0), 51-154 dpm (0), 75%176dpm (A), 
67-165 dpm (A) or 47-143 dpm (o)] were 5-26% (0) 
0.4-l% (0), 0.7-2% (A), 0.8-2% (A) or 0.7-3% (0) of the 
100% values. The theoretical curves have been drawn by 
nonlinear least-squares analysis as in [4]. The lC50 values of 
hexahydrosiladifenidol, pirenzepine and AF-DX 116 were 
302 nM, 105 nM and 15.5 gM for mAChR I; 1.17 ,uM, 2.75 FM 
and3.16pM for mAChR II; 21.4 nM, 813 nM and ll.OpM for 
porcine mAChR III; 20.9 nM, 646 nM and 16.6pM for rat 
mAChR III; and 107 nM, 646 nM and 12.6 pM for mAChR 
IV, respectively. 
most closely to the pharmacologically defined Mi 
(I), MZ cardiac (II) and MZ glandular (III) sub- 
types, respectively. In support of this view is the 
differential tissue location of the mRNAs encoding 
g 100 
z a 60 
n 
z 60 
7 40 
% 
I 20 
0 
60. 
40. 
20- 
[Antagonist] (M) 
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these mAChR species, revealed by blot hybridiza- 
tion analysis [4,5,9]. Thus, the mAChR 
heterogeneity in tissues with respect to antagonist 
binding can be accounted for by the presence of in- 
dividual molecularly distinct mAChR species or 
various combinations of them. 
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